Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2].
Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor[2].
| Animal Model: | Rag1KO-Tg KIR mice injected with tumor cells[2] |
| Dosage: | 15 mg/kg |
| Administration: | intravenous injection; 15 mg/kg; once |
| Result: | Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died. |
[1]. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478.
[2]. Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86.